A Multicenter, Non-comparative, Phase IV Study to Evaluate the Effect of Candesartan Based Therapy in the Percent Change of proBNP Level After 24 Week Treatment in the Patients With Hypertension With Left Ventricular Hypertrophy.
Phase of Trial: Phase IV
Latest Information Update: 30 Mar 2012
At a glance
- Drugs Candesartan cilexetil; Felodipine
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 07 Oct 2008 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 10 Aug 2008 Actual study completion date added as reported by ClinicalTrials.gov.